Richard E Pratley
Overview
Explore the profile of Richard E Pratley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
242
Citations
8325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kudva Y, Henderson R, Kanapka L, Weinstock R, Rickels M, Pratley R, et al.
Diabetes Technol Ther
. 2025 Mar;
PMID: 40067490
The Automated Insulin Delivery in Elderly with Type 1 Diabetes (AIDE T1D) trial randomized 82 adults ≥65 years with type 1 diabetes (T1D) to hybrid closed loop (HCL), predictive low...
2.
Cherney D, Frederich R, Pratley R, Cosentino F, Dagogo-Jack S, Pong A, et al.
Kidney Dis (Basel)
. 2025 Mar;
11(1):63-74.
PMID: 40028005
Introduction: VERTIS CV was a placebo-controlled cardiovascular (CV) outcome trial evaluating the sodium-glucose cotransporter 2 inhibitor ertugliflozin in patients with type 2 diabetes and established atherosclerotic CV disease. The aim...
3.
Fonseca L, Hawks Z, Beeri M, Jung L, Kudva Y, Rizvi S, et al.
Alzheimers Dement
. 2025 Feb;
21(2):e70001.
PMID: 39991795
Introduction: Cognition is reduced at low and high glucose, reflecting cognitive vulnerability to glucose (CVG) fluctuations. The impact of glucose fluctuations on the aging brain remains unclear. We examined whether...
4.
Munshi M, Kahkoska A, Neumiller J, Alexopoulos A, Allen N, Cukierman-Yaffe T, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
PMID: 39978368
Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ability to perform self-care. Most diabetes guidelines focus on improving glycaemia through addition...
5.
Pandey A, Kolkailah A, McGuire D, Frederich R, Cater N, Cosentino F, et al.
Eur J Heart Fail
. 2025 Jan;
PMID: 39792342
Aims: In VERTIS CV, ertugliflozin was associated with a 30% risk reduction for adjudication-confirmed, first and total hospitalizations for heart failure (HHF) in participants with type 2 diabetes and atherosclerotic...
6.
Kudva Y, Henderson R, Kanapka L, Weinstock R, Rickels M, Pratley R, et al.
NEJM Evid
. 2024 Dec;
4(1):EVIDoa2400200.
PMID: 39714936
Background: Older adults with type 1 diabetes are at risk for serious hypoglycemia. Automated insulin delivery can reduce risk but has not been sufficiently evaluated in this population. Methods: We...
7.
Cosentino F, Dagogo-Jack S, Frederich R, Cannon C, Cherney D, Mancuso J, et al.
Diabetes Obes Metab
. 2024 Dec;
27(2):583-594.
PMID: 39696829
Aim: To assess weight loss and cardiorenal outcomes by baseline body mass index (BMI) in VERTIS CV. Methods: Patients with type 2 diabetes and atherosclerotic cardiovascular (CV) disease were randomized...
8.
Badve S, Bilal A, Lee M, Sattar N, Gerstein H, Ruff C, et al.
Lancet Diabetes Endocrinol
. 2024 Nov;
13(1):15-28.
PMID: 39608381
Background: GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) and can also have kidney benefits. However, whether GLP-1 receptor agonists improve clinically important kidney outcomes remains...
9.
Serrano J, Kondo S, Link G, Brown I, Pratley R, Baskin K, et al.
Metabolism
. 2024 Oct;
162:156045.
PMID: 39393515
Background: The TAS1R2 receptor, known for its role in taste perception, has also emerged as a key regulator of muscle physiology. Previous studies have shown that genetic ablation of TAS1R2...
10.
Sridhar V, Cosentino F, Dagogo-Jack S, McGuire D, Pratley R, Cater N, et al.
Diabetes Obes Metab
. 2024 Sep;
26(11):5336-5346.
PMID: 39219437
Aim: To conduct post hoc analyses of the VERTIS CV (NCT01986881) trial to explore the effects of ertugliflozin on serum uric acid (UA) and gout-related outcomes. Materials And Methods: Participants...